Mydecine Innovations Group Public Offering led by Canaccord Genuity Corp.

As an emerging BioPharma and life sciences company, Mydecine is currently researching and developing alternative natural medicines and constructing a drug pipeline for the psychedelic industry. Bought stock offering with Canaccord will increase Mydecine capital by almost 20 million dollars!